nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimethoprim—CYP2C8—Sorafenib—thyroid cancer	0.119	0.243	CbGbCtD
Trimethoprim—CYP2C9—Sorafenib—thyroid cancer	0.0833	0.17	CbGbCtD
Trimethoprim—ABCB1—Sorafenib—thyroid cancer	0.0809	0.165	CbGbCtD
Trimethoprim—CYP3A4—Vandetanib—thyroid cancer	0.0804	0.164	CbGbCtD
Trimethoprim—ABCB1—Doxorubicin—thyroid cancer	0.0491	0.0999	CbGbCtD
Trimethoprim—CYP3A4—Sorafenib—thyroid cancer	0.0485	0.0987	CbGbCtD
Trimethoprim—CYP3A4—Doxorubicin—thyroid cancer	0.0294	0.0599	CbGbCtD
Trimethoprim—DHFR—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.0106	0.0986	CbGpPWpGaD
Trimethoprim—TYMS—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.00921	0.0861	CbGpPWpGaD
Trimethoprim—TYMS—Erlotinib—Vandetanib—thyroid cancer	0.00724	0.449	CbGdCrCtD
Trimethoprim—DHFR—G1/S-Specific Transcription—CDK1—thyroid cancer	0.00561	0.0525	CbGpPWpGaD
Trimethoprim—TYMS—G1/S-Specific Transcription—CDK1—thyroid cancer	0.0049	0.0458	CbGpPWpGaD
Trimethoprim—TYMS—Afatinib—Vandetanib—thyroid cancer	0.00474	0.294	CbGdCrCtD
Trimethoprim—TYMS—Gefitinib—Vandetanib—thyroid cancer	0.00414	0.257	CbGdCrCtD
Trimethoprim—DHFR—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00341	0.0319	CbGpPWpGaD
Trimethoprim—DHFR—E2F mediated regulation of DNA replication—CDK1—thyroid cancer	0.0033	0.0309	CbGpPWpGaD
Trimethoprim—TYMS—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00298	0.0278	CbGpPWpGaD
Trimethoprim—TYMS—E2F mediated regulation of DNA replication—CDK1—thyroid cancer	0.00288	0.0269	CbGpPWpGaD
Trimethoprim—Eruption—Epirubicin—thyroid cancer	0.00239	0.00619	CcSEcCtD
Trimethoprim—Neutropenia—Sorafenib—thyroid cancer	0.00233	0.00604	CcSEcCtD
Trimethoprim—Loss of consciousness—Vandetanib—thyroid cancer	0.00226	0.00587	CcSEcCtD
Trimethoprim—Cough—Vandetanib—thyroid cancer	0.00225	0.00583	CcSEcCtD
Trimethoprim—Pneumonia—Sorafenib—thyroid cancer	0.00224	0.0058	CcSEcCtD
Trimethoprim—Convulsion—Vandetanib—thyroid cancer	0.00223	0.00578	CcSEcCtD
Trimethoprim—Infestation NOS—Sorafenib—thyroid cancer	0.00222	0.00576	CcSEcCtD
Trimethoprim—Infestation—Sorafenib—thyroid cancer	0.00222	0.00576	CcSEcCtD
Trimethoprim—Eruption—Doxorubicin—thyroid cancer	0.00221	0.00573	CcSEcCtD
Trimethoprim—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.0022	0.00571	CcSEcCtD
Trimethoprim—Arthralgia—Vandetanib—thyroid cancer	0.00219	0.00568	CcSEcCtD
Trimethoprim—Renal failure—Sorafenib—thyroid cancer	0.00219	0.00567	CcSEcCtD
Trimethoprim—Anxiety—Vandetanib—thyroid cancer	0.00219	0.00566	CcSEcCtD
Trimethoprim—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00218	0.00565	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00218	0.00564	CcSEcCtD
Trimethoprim—Bone marrow depression—Epirubicin—thyroid cancer	0.00218	0.00564	CcSEcCtD
Trimethoprim—Stomatitis—Sorafenib—thyroid cancer	0.00217	0.00562	CcSEcCtD
Trimethoprim—Hepatobiliary disease—Sorafenib—thyroid cancer	0.0021	0.00545	CcSEcCtD
Trimethoprim—Epistaxis—Sorafenib—thyroid cancer	0.0021	0.00544	CcSEcCtD
Trimethoprim—Nervous system disorder—Vandetanib—thyroid cancer	0.00206	0.00534	CcSEcCtD
Trimethoprim—Thrombocytopenia—Vandetanib—thyroid cancer	0.00206	0.00533	CcSEcCtD
Trimethoprim—Skin disorder—Vandetanib—thyroid cancer	0.00204	0.00529	CcSEcCtD
Trimethoprim—Bone marrow depression—Doxorubicin—thyroid cancer	0.00201	0.00522	CcSEcCtD
Trimethoprim—Urinary tract disorder—Sorafenib—thyroid cancer	0.00197	0.00511	CcSEcCtD
Trimethoprim—Neuritis—Epirubicin—thyroid cancer	0.00197	0.0051	CcSEcCtD
Trimethoprim—Connective tissue disorder—Sorafenib—thyroid cancer	0.00196	0.00508	CcSEcCtD
Trimethoprim—Urethral disorder—Sorafenib—thyroid cancer	0.00196	0.00507	CcSEcCtD
Trimethoprim—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00192	0.00496	CcSEcCtD
Trimethoprim—Insomnia—Vandetanib—thyroid cancer	0.0019	0.00493	CcSEcCtD
Trimethoprim—Erythema multiforme—Sorafenib—thyroid cancer	0.00189	0.00489	CcSEcCtD
Trimethoprim—CYP2C8—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00188	0.0176	CbGpPWpGaD
Trimethoprim—Dyspnoea—Vandetanib—thyroid cancer	0.00187	0.00486	CcSEcCtD
Trimethoprim—Tinnitus—Sorafenib—thyroid cancer	0.00186	0.00482	CcSEcCtD
Trimethoprim—Dyspepsia—Vandetanib—thyroid cancer	0.00185	0.0048	CcSEcCtD
Trimethoprim—Decreased appetite—Vandetanib—thyroid cancer	0.00183	0.00474	CcSEcCtD
Trimethoprim—Neuritis—Doxorubicin—thyroid cancer	0.00182	0.00472	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00181	0.0047	CcSEcCtD
Trimethoprim—Immune system disorder—Sorafenib—thyroid cancer	0.0018	0.00467	CcSEcCtD
Trimethoprim—Mediastinal disorder—Sorafenib—thyroid cancer	0.0018	0.00466	CcSEcCtD
Trimethoprim—Constipation—Vandetanib—thyroid cancer	0.0018	0.00466	CcSEcCtD
Trimethoprim—DHFR—E2F transcription factor network—CDK1—thyroid cancer	0.00175	0.0163	CbGpPWpGaD
Trimethoprim—Mental disorder—Sorafenib—thyroid cancer	0.00175	0.00453	CcSEcCtD
Trimethoprim—Erythema—Sorafenib—thyroid cancer	0.00174	0.0045	CcSEcCtD
Trimethoprim—Malnutrition—Sorafenib—thyroid cancer	0.00174	0.0045	CcSEcCtD
Trimethoprim—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00172	0.00446	CcSEcCtD
Trimethoprim—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—thyroid cancer	0.00172	0.0161	CbGpPWpGaD
Trimethoprim—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00167	0.00433	CcSEcCtD
Trimethoprim—Body temperature increased—Vandetanib—thyroid cancer	0.00166	0.00431	CcSEcCtD
Trimethoprim—Abdominal pain—Vandetanib—thyroid cancer	0.00166	0.00431	CcSEcCtD
Trimethoprim—Glossitis—Epirubicin—thyroid cancer	0.00159	0.00413	CcSEcCtD
Trimethoprim—Angioedema—Sorafenib—thyroid cancer	0.00159	0.00412	CcSEcCtD
Trimethoprim—Dyskinesia—Epirubicin—thyroid cancer	0.00156	0.00405	CcSEcCtD
Trimethoprim—Syncope—Sorafenib—thyroid cancer	0.00156	0.00404	CcSEcCtD
Trimethoprim—Leukopenia—Sorafenib—thyroid cancer	0.00156	0.00403	CcSEcCtD
Trimethoprim—TYMS—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00155	0.0145	CbGpPWpGaD
Trimethoprim—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00155	0.00401	CcSEcCtD
Trimethoprim—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00153	0.0143	CbGpPWpGaD
Trimethoprim—Loss of consciousness—Sorafenib—thyroid cancer	0.00153	0.00396	CcSEcCtD
Trimethoprim—TYMS—E2F transcription factor network—CDK1—thyroid cancer	0.00153	0.0143	CbGpPWpGaD
Trimethoprim—DHFR—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00152	0.0142	CbGpPWpGaD
Trimethoprim—Cough—Sorafenib—thyroid cancer	0.00152	0.00393	CcSEcCtD
Trimethoprim—Pruritus—Vandetanib—thyroid cancer	0.00149	0.00386	CcSEcCtD
Trimethoprim—Arthralgia—Sorafenib—thyroid cancer	0.00148	0.00383	CcSEcCtD
Trimethoprim—Myalgia—Sorafenib—thyroid cancer	0.00148	0.00383	CcSEcCtD
Trimethoprim—Glossitis—Doxorubicin—thyroid cancer	0.00147	0.00382	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00147	0.00381	CcSEcCtD
Trimethoprim—Dyskinesia—Doxorubicin—thyroid cancer	0.00145	0.00375	CcSEcCtD
Trimethoprim—Hyperkalaemia—Epirubicin—thyroid cancer	0.00144	0.00374	CcSEcCtD
Trimethoprim—Diarrhoea—Vandetanib—thyroid cancer	0.00144	0.00373	CcSEcCtD
Trimethoprim—Anaphylactic shock—Sorafenib—thyroid cancer	0.00142	0.00368	CcSEcCtD
Trimethoprim—Shock—Sorafenib—thyroid cancer	0.0014	0.00362	CcSEcCtD
Trimethoprim—Nervous system disorder—Sorafenib—thyroid cancer	0.00139	0.0036	CcSEcCtD
Trimethoprim—Dizziness—Vandetanib—thyroid cancer	0.00139	0.0036	CcSEcCtD
Trimethoprim—Thrombocytopenia—Sorafenib—thyroid cancer	0.00139	0.0036	CcSEcCtD
Trimethoprim—Aplastic anaemia—Epirubicin—thyroid cancer	0.00138	0.00357	CcSEcCtD
Trimethoprim—Skin disorder—Sorafenib—thyroid cancer	0.00138	0.00357	CcSEcCtD
Trimethoprim—Anorexia—Sorafenib—thyroid cancer	0.00135	0.0035	CcSEcCtD
Trimethoprim—Vomiting—Vandetanib—thyroid cancer	0.00134	0.00346	CcSEcCtD
Trimethoprim—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00134	0.00346	CcSEcCtD
Trimethoprim—TYMS—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00133	0.0124	CbGpPWpGaD
Trimethoprim—Rash—Vandetanib—thyroid cancer	0.00133	0.00344	CcSEcCtD
Trimethoprim—Dermatitis—Vandetanib—thyroid cancer	0.00132	0.00343	CcSEcCtD
Trimethoprim—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00132	0.0123	CbGpPWpGaD
Trimethoprim—Headache—Vandetanib—thyroid cancer	0.00132	0.00341	CcSEcCtD
Trimethoprim—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00129	0.00335	CcSEcCtD
Trimethoprim—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00128	0.00331	CcSEcCtD
Trimethoprim—DHFR—G1/S Transition—CDK1—thyroid cancer	0.00127	0.0119	CbGpPWpGaD
Trimethoprim—Dyspnoea—Sorafenib—thyroid cancer	0.00126	0.00328	CcSEcCtD
Trimethoprim—Nausea—Vandetanib—thyroid cancer	0.00125	0.00324	CcSEcCtD
Trimethoprim—Dyspepsia—Sorafenib—thyroid cancer	0.00125	0.00324	CcSEcCtD
Trimethoprim—Decreased appetite—Sorafenib—thyroid cancer	0.00123	0.0032	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00122	0.00317	CcSEcCtD
Trimethoprim—Photosensitivity—Epirubicin—thyroid cancer	0.00121	0.00315	CcSEcCtD
Trimethoprim—Constipation—Sorafenib—thyroid cancer	0.00121	0.00314	CcSEcCtD
Trimethoprim—Vascular purpura—Epirubicin—thyroid cancer	0.00119	0.00309	CcSEcCtD
Trimethoprim—DHFR—Metabolism of nitric oxide—AKT1—thyroid cancer	0.00119	0.0111	CbGpPWpGaD
Trimethoprim—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00116	0.00301	CcSEcCtD
Trimethoprim—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00113	0.00293	CcSEcCtD
Trimethoprim—Urticaria—Sorafenib—thyroid cancer	0.00113	0.00292	CcSEcCtD
Trimethoprim—Photosensitivity—Doxorubicin—thyroid cancer	0.00112	0.00291	CcSEcCtD
Trimethoprim—Abdominal pain—Sorafenib—thyroid cancer	0.00112	0.00291	CcSEcCtD
Trimethoprim—Body temperature increased—Sorafenib—thyroid cancer	0.00112	0.00291	CcSEcCtD
Trimethoprim—Renal impairment—Epirubicin—thyroid cancer	0.00112	0.0029	CcSEcCtD
Trimethoprim—Dermatitis bullous—Epirubicin—thyroid cancer	0.00112	0.00289	CcSEcCtD
Trimethoprim—TYMS—G1/S Transition—CDK1—thyroid cancer	0.00111	0.0104	CbGpPWpGaD
Trimethoprim—Purpura—Epirubicin—thyroid cancer	0.00111	0.00287	CcSEcCtD
Trimethoprim—Vascular purpura—Doxorubicin—thyroid cancer	0.0011	0.00286	CcSEcCtD
Trimethoprim—Hypoglycaemia—Epirubicin—thyroid cancer	0.00109	0.00283	CcSEcCtD
Trimethoprim—Lethargy—Epirubicin—thyroid cancer	0.00109	0.00282	CcSEcCtD
Trimethoprim—Hyponatraemia—Epirubicin—thyroid cancer	0.00107	0.00277	CcSEcCtD
Trimethoprim—DHFR—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.00107	0.01	CbGpPWpGaD
Trimethoprim—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00105	0.00271	CcSEcCtD
Trimethoprim—Hypersensitivity—Sorafenib—thyroid cancer	0.00104	0.00271	CcSEcCtD
Trimethoprim—Renal impairment—Doxorubicin—thyroid cancer	0.00104	0.00269	CcSEcCtD
Trimethoprim—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00103	0.00268	CcSEcCtD
Trimethoprim—Purpura—Doxorubicin—thyroid cancer	0.00102	0.00265	CcSEcCtD
Trimethoprim—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00101	0.00262	CcSEcCtD
Trimethoprim—Lethargy—Doxorubicin—thyroid cancer	0.00101	0.00261	CcSEcCtD
Trimethoprim—Pruritus—Sorafenib—thyroid cancer	0.001	0.0026	CcSEcCtD
Trimethoprim—Ataxia—Epirubicin—thyroid cancer	0.001	0.0026	CcSEcCtD
Trimethoprim—Hyponatraemia—Doxorubicin—thyroid cancer	0.000991	0.00257	CcSEcCtD
Trimethoprim—Diarrhoea—Sorafenib—thyroid cancer	0.00097	0.00251	CcSEcCtD
Trimethoprim—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00096	0.00249	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.000947	0.00886	CbGpPWpGaD
Trimethoprim—Dizziness—Sorafenib—thyroid cancer	0.000938	0.00243	CcSEcCtD
Trimethoprim—TYMS—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.000933	0.00872	CbGpPWpGaD
Trimethoprim—Ataxia—Doxorubicin—thyroid cancer	0.000928	0.0024	CcSEcCtD
Trimethoprim—Eosinophilia—Epirubicin—thyroid cancer	0.000913	0.00237	CcSEcCtD
Trimethoprim—DHFR—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000906	0.00847	CbGpPWpGaD
Trimethoprim—Pancreatitis—Epirubicin—thyroid cancer	0.000904	0.00234	CcSEcCtD
Trimethoprim—Vomiting—Sorafenib—thyroid cancer	0.000902	0.00234	CcSEcCtD
Trimethoprim—Rash—Sorafenib—thyroid cancer	0.000894	0.00232	CcSEcCtD
Trimethoprim—Dermatitis—Sorafenib—thyroid cancer	0.000893	0.00232	CcSEcCtD
Trimethoprim—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000888	0.0023	CcSEcCtD
Trimethoprim—Headache—Sorafenib—thyroid cancer	0.000888	0.0023	CcSEcCtD
Trimethoprim—Pancytopenia—Epirubicin—thyroid cancer	0.000875	0.00227	CcSEcCtD
Trimethoprim—Neutropenia—Epirubicin—thyroid cancer	0.000862	0.00223	CcSEcCtD
Trimethoprim—CYP2C8—Metapathway biotransformation—CHST14—thyroid cancer	0.000856	0.008	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—PCM1—thyroid cancer	0.000847	0.00792	CbGpPWpGaD
Trimethoprim—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000845	0.0079	CbGpPWpGaD
Trimethoprim—Eosinophilia—Doxorubicin—thyroid cancer	0.000844	0.00219	CcSEcCtD
Trimethoprim—Nausea—Sorafenib—thyroid cancer	0.000842	0.00218	CcSEcCtD
Trimethoprim—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000841	0.00218	CcSEcCtD
Trimethoprim—Pancreatitis—Doxorubicin—thyroid cancer	0.000836	0.00217	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.000827	0.00773	CbGpPWpGaD
Trimethoprim—Pneumonia—Epirubicin—thyroid cancer	0.000827	0.00214	CcSEcCtD
Trimethoprim—Infestation—Epirubicin—thyroid cancer	0.000822	0.00213	CcSEcCtD
Trimethoprim—Infestation NOS—Epirubicin—thyroid cancer	0.000822	0.00213	CcSEcCtD
Trimethoprim—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000815	0.00211	CcSEcCtD
Trimethoprim—Pancytopenia—Doxorubicin—thyroid cancer	0.00081	0.0021	CcSEcCtD
Trimethoprim—Renal failure—Epirubicin—thyroid cancer	0.000808	0.00209	CcSEcCtD
Trimethoprim—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000806	0.00209	CcSEcCtD
Trimethoprim—Stomatitis—Epirubicin—thyroid cancer	0.000801	0.00208	CcSEcCtD
Trimethoprim—Neutropenia—Doxorubicin—thyroid cancer	0.000797	0.00207	CcSEcCtD
Trimethoprim—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00079	0.00739	CbGpPWpGaD
Trimethoprim—TYMS—Fluoropyrimidine Activity—TP53—thyroid cancer	0.00079	0.00739	CbGpPWpGaD
Trimethoprim—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00079	0.00738	CbGpPWpGaD
Trimethoprim—Haematuria—Epirubicin—thyroid cancer	0.000784	0.00203	CcSEcCtD
Trimethoprim—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000778	0.00202	CcSEcCtD
Trimethoprim—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000777	0.00201	CcSEcCtD
Trimethoprim—Epistaxis—Epirubicin—thyroid cancer	0.000775	0.00201	CcSEcCtD
Trimethoprim—Agranulocytosis—Epirubicin—thyroid cancer	0.000767	0.00199	CcSEcCtD
Trimethoprim—Pneumonia—Doxorubicin—thyroid cancer	0.000765	0.00198	CcSEcCtD
Trimethoprim—Infestation—Doxorubicin—thyroid cancer	0.00076	0.00197	CcSEcCtD
Trimethoprim—Infestation NOS—Doxorubicin—thyroid cancer	0.00076	0.00197	CcSEcCtD
Trimethoprim—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000754	0.00195	CcSEcCtD
Trimethoprim—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000753	0.00704	CbGpPWpGaD
Trimethoprim—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.00075	0.00701	CbGpPWpGaD
Trimethoprim—Renal failure—Doxorubicin—thyroid cancer	0.000747	0.00194	CcSEcCtD
Trimethoprim—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000745	0.00193	CcSEcCtD
Trimethoprim—Stomatitis—Doxorubicin—thyroid cancer	0.000741	0.00192	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle—PCM1—thyroid cancer	0.000739	0.00691	CbGpPWpGaD
Trimethoprim—Urinary tract disorder—Epirubicin—thyroid cancer	0.000729	0.00189	CcSEcCtD
Trimethoprim—Haematuria—Doxorubicin—thyroid cancer	0.000725	0.00188	CcSEcCtD
Trimethoprim—Connective tissue disorder—Epirubicin—thyroid cancer	0.000725	0.00188	CcSEcCtD
Trimethoprim—Urethral disorder—Epirubicin—thyroid cancer	0.000723	0.00187	CcSEcCtD
Trimethoprim—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000719	0.00186	CcSEcCtD
Trimethoprim—Epistaxis—Doxorubicin—thyroid cancer	0.000717	0.00186	CcSEcCtD
Trimethoprim—Agranulocytosis—Doxorubicin—thyroid cancer	0.00071	0.00184	CcSEcCtD
Trimethoprim—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—thyroid cancer	0.000701	0.00655	CbGpPWpGaD
Trimethoprim—Erythema multiforme—Epirubicin—thyroid cancer	0.000697	0.00181	CcSEcCtD
Trimethoprim—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000697	0.00651	CbGpPWpGaD
Trimethoprim—Eye disorder—Epirubicin—thyroid cancer	0.000689	0.00179	CcSEcCtD
Trimethoprim—Tinnitus—Epirubicin—thyroid cancer	0.000688	0.00178	CcSEcCtD
Trimethoprim—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000674	0.00175	CcSEcCtD
Trimethoprim—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000671	0.00174	CcSEcCtD
Trimethoprim—Urethral disorder—Doxorubicin—thyroid cancer	0.000669	0.00173	CcSEcCtD
Trimethoprim—Immune system disorder—Epirubicin—thyroid cancer	0.000666	0.00173	CcSEcCtD
Trimethoprim—Mediastinal disorder—Epirubicin—thyroid cancer	0.000665	0.00172	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000656	0.00613	CbGpPWpGaD
Trimethoprim—Mental disorder—Epirubicin—thyroid cancer	0.000646	0.00168	CcSEcCtD
Trimethoprim—Erythema multiforme—Doxorubicin—thyroid cancer	0.000645	0.00167	CcSEcCtD
Trimethoprim—Malnutrition—Epirubicin—thyroid cancer	0.000642	0.00166	CcSEcCtD
Trimethoprim—Erythema—Epirubicin—thyroid cancer	0.000642	0.00166	CcSEcCtD
Trimethoprim—Eye disorder—Doxorubicin—thyroid cancer	0.000638	0.00165	CcSEcCtD
Trimethoprim—Tinnitus—Doxorubicin—thyroid cancer	0.000636	0.00165	CcSEcCtD
Trimethoprim—DHFR—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000633	0.00592	CbGpPWpGaD
Trimethoprim—Immune system disorder—Doxorubicin—thyroid cancer	0.000617	0.0016	CcSEcCtD
Trimethoprim—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000615	0.00159	CcSEcCtD
Trimethoprim—DHFR—Disease—TRIM24—thyroid cancer	0.00061	0.0057	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—MINPP1—thyroid cancer	0.000601	0.00562	CbGpPWpGaD
Trimethoprim—Mental disorder—Doxorubicin—thyroid cancer	0.000598	0.00155	CcSEcCtD
Trimethoprim—Malnutrition—Doxorubicin—thyroid cancer	0.000594	0.00154	CcSEcCtD
Trimethoprim—Erythema—Doxorubicin—thyroid cancer	0.000594	0.00154	CcSEcCtD
Trimethoprim—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000591	0.00553	CbGpPWpGaD
Trimethoprim—Agitation—Epirubicin—thyroid cancer	0.00059	0.00153	CcSEcCtD
Trimethoprim—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000587	0.00549	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000579	0.00541	CbGpPWpGaD
Trimethoprim—Vertigo—Epirubicin—thyroid cancer	0.000577	0.0015	CcSEcCtD
Trimethoprim—Syncope—Epirubicin—thyroid cancer	0.000576	0.00149	CcSEcCtD
Trimethoprim—Leukopenia—Epirubicin—thyroid cancer	0.000575	0.00149	CcSEcCtD
Trimethoprim—DHFR—Disease—CHST14—thyroid cancer	0.000573	0.00536	CbGpPWpGaD
Trimethoprim—Loss of consciousness—Epirubicin—thyroid cancer	0.000564	0.00146	CcSEcCtD
Trimethoprim—Cough—Epirubicin—thyroid cancer	0.00056	0.00145	CcSEcCtD
Trimethoprim—Convulsion—Epirubicin—thyroid cancer	0.000556	0.00144	CcSEcCtD
Trimethoprim—TYMS—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000552	0.00516	CbGpPWpGaD
Trimethoprim—Myalgia—Epirubicin—thyroid cancer	0.000547	0.00142	CcSEcCtD
Trimethoprim—Arthralgia—Epirubicin—thyroid cancer	0.000547	0.00142	CcSEcCtD
Trimethoprim—Agitation—Doxorubicin—thyroid cancer	0.000546	0.00142	CcSEcCtD
Trimethoprim—Anxiety—Epirubicin—thyroid cancer	0.000545	0.00141	CcSEcCtD
Trimethoprim—DHFR—Disease—TRIM33—thyroid cancer	0.000544	0.00508	CbGpPWpGaD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000543	0.00141	CcSEcCtD
Trimethoprim—Vertigo—Doxorubicin—thyroid cancer	0.000534	0.00138	CcSEcCtD
Trimethoprim—Syncope—Doxorubicin—thyroid cancer	0.000533	0.00138	CcSEcCtD
Trimethoprim—Leukopenia—Doxorubicin—thyroid cancer	0.000532	0.00138	CcSEcCtD
Trimethoprim—Confusional state—Epirubicin—thyroid cancer	0.000528	0.00137	CcSEcCtD
Trimethoprim—TYMS—Metabolism—MINPP1—thyroid cancer	0.000524	0.0049	CbGpPWpGaD
Trimethoprim—Anaphylactic shock—Epirubicin—thyroid cancer	0.000524	0.00136	CcSEcCtD
Trimethoprim—Loss of consciousness—Doxorubicin—thyroid cancer	0.000522	0.00135	CcSEcCtD
Trimethoprim—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000521	0.00487	CbGpPWpGaD
Trimethoprim—DHFR—Folate Metabolism—TP53—thyroid cancer	0.00052	0.00486	CbGpPWpGaD
Trimethoprim—Cough—Doxorubicin—thyroid cancer	0.000519	0.00134	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle—TPR—thyroid cancer	0.000518	0.00484	CbGpPWpGaD
Trimethoprim—Shock—Epirubicin—thyroid cancer	0.000516	0.00134	CcSEcCtD
Trimethoprim—Convulsion—Doxorubicin—thyroid cancer	0.000515	0.00133	CcSEcCtD
Trimethoprim—Nervous system disorder—Epirubicin—thyroid cancer	0.000514	0.00133	CcSEcCtD
Trimethoprim—Thrombocytopenia—Epirubicin—thyroid cancer	0.000513	0.00133	CcSEcCtD
Trimethoprim—DHFR—Metabolism—NDUFA13—thyroid cancer	0.000511	0.00478	CbGpPWpGaD
Trimethoprim—Skin disorder—Epirubicin—thyroid cancer	0.000509	0.00132	CcSEcCtD
Trimethoprim—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000508	0.00475	CbGpPWpGaD
Trimethoprim—Myalgia—Doxorubicin—thyroid cancer	0.000506	0.00131	CcSEcCtD
Trimethoprim—Arthralgia—Doxorubicin—thyroid cancer	0.000506	0.00131	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000505	0.00472	CbGpPWpGaD
Trimethoprim—Anxiety—Doxorubicin—thyroid cancer	0.000504	0.00131	CcSEcCtD
Trimethoprim—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000502	0.0013	CcSEcCtD
Trimethoprim—Anorexia—Epirubicin—thyroid cancer	0.0005	0.00129	CcSEcCtD
Trimethoprim—Confusional state—Doxorubicin—thyroid cancer	0.000489	0.00127	CcSEcCtD
Trimethoprim—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000485	0.00126	CcSEcCtD
Trimethoprim—DHFR—Metabolism—CHST14—thyroid cancer	0.00048	0.00449	CbGpPWpGaD
Trimethoprim—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000478	0.00447	CbGpPWpGaD
Trimethoprim—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000477	0.00124	CcSEcCtD
Trimethoprim—Shock—Doxorubicin—thyroid cancer	0.000477	0.00124	CcSEcCtD
Trimethoprim—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000476	0.00445	CbGpPWpGaD
Trimethoprim—Nervous system disorder—Doxorubicin—thyroid cancer	0.000476	0.00123	CcSEcCtD
Trimethoprim—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000475	0.00444	CbGpPWpGaD
Trimethoprim—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000475	0.00123	CcSEcCtD
Trimethoprim—Insomnia—Epirubicin—thyroid cancer	0.000474	0.00123	CcSEcCtD
Trimethoprim—Skin disorder—Doxorubicin—thyroid cancer	0.000471	0.00122	CcSEcCtD
Trimethoprim—Dyspnoea—Epirubicin—thyroid cancer	0.000467	0.00121	CcSEcCtD
Trimethoprim—Anorexia—Doxorubicin—thyroid cancer	0.000462	0.0012	CcSEcCtD
Trimethoprim—Dyspepsia—Epirubicin—thyroid cancer	0.000461	0.0012	CcSEcCtD
Trimethoprim—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000459	0.0043	CbGpPWpGaD
Trimethoprim—Decreased appetite—Epirubicin—thyroid cancer	0.000456	0.00118	CcSEcCtD
Trimethoprim—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000452	0.00117	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle—TPR—thyroid cancer	0.000452	0.00422	CbGpPWpGaD
Trimethoprim—Constipation—Epirubicin—thyroid cancer	0.000448	0.00116	CcSEcCtD
Trimethoprim—TYMS—Metabolism—NDUFA13—thyroid cancer	0.000446	0.00417	CbGpPWpGaD
Trimethoprim—DHFR—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000445	0.00416	CbGpPWpGaD
Trimethoprim—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000442	0.00115	CcSEcCtD
Trimethoprim—Insomnia—Doxorubicin—thyroid cancer	0.000439	0.00114	CcSEcCtD
Trimethoprim—Dyspnoea—Doxorubicin—thyroid cancer	0.000432	0.00112	CcSEcCtD
Trimethoprim—Feeling abnormal—Epirubicin—thyroid cancer	0.000432	0.00112	CcSEcCtD
Trimethoprim—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000429	0.00111	CcSEcCtD
Trimethoprim—Dyspepsia—Doxorubicin—thyroid cancer	0.000427	0.00111	CcSEcCtD
Trimethoprim—Decreased appetite—Doxorubicin—thyroid cancer	0.000422	0.00109	CcSEcCtD
Trimethoprim—TYMS—Metabolism—CHST14—thyroid cancer	0.000419	0.00392	CbGpPWpGaD
Trimethoprim—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000419	0.00109	CcSEcCtD
Trimethoprim—DHFR—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000417	0.0039	CbGpPWpGaD
Trimethoprim—Urticaria—Epirubicin—thyroid cancer	0.000416	0.00108	CcSEcCtD
Trimethoprim—Constipation—Doxorubicin—thyroid cancer	0.000415	0.00107	CcSEcCtD
Trimethoprim—Abdominal pain—Epirubicin—thyroid cancer	0.000414	0.00107	CcSEcCtD
Trimethoprim—Body temperature increased—Epirubicin—thyroid cancer	0.000414	0.00107	CcSEcCtD
Trimethoprim—Feeling abnormal—Doxorubicin—thyroid cancer	0.0004	0.00104	CcSEcCtD
Trimethoprim—TYMS—Circadian rythm related genes—PPARG—thyroid cancer	0.000398	0.00372	CbGpPWpGaD
Trimethoprim—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000397	0.00103	CcSEcCtD
Trimethoprim—DHFR—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000392	0.00367	CbGpPWpGaD
Trimethoprim—TYMS—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000389	0.00363	CbGpPWpGaD
Trimethoprim—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000387	0.00362	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—HPGD—thyroid cancer	0.000387	0.00362	CbGpPWpGaD
Trimethoprim—Hypersensitivity—Epirubicin—thyroid cancer	0.000386	0.001	CcSEcCtD
Trimethoprim—Urticaria—Doxorubicin—thyroid cancer	0.000385	0.000998	CcSEcCtD
Trimethoprim—Abdominal pain—Doxorubicin—thyroid cancer	0.000383	0.000994	CcSEcCtD
Trimethoprim—Body temperature increased—Doxorubicin—thyroid cancer	0.000383	0.000994	CcSEcCtD
Trimethoprim—Pruritus—Epirubicin—thyroid cancer	0.000371	0.000961	CcSEcCtD
Trimethoprim—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000368	0.00344	CbGpPWpGaD
Trimethoprim—TYMS—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000364	0.0034	CbGpPWpGaD
Trimethoprim—DHFR—Disease—TCF7L1—thyroid cancer	0.000363	0.00339	CbGpPWpGaD
Trimethoprim—Diarrhoea—Epirubicin—thyroid cancer	0.000359	0.000929	CcSEcCtD
Trimethoprim—Hypersensitivity—Doxorubicin—thyroid cancer	0.000357	0.000926	CcSEcCtD
Trimethoprim—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000352	0.00329	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—CDK1—thyroid cancer	0.000351	0.00328	CbGpPWpGaD
Trimethoprim—Dizziness—Epirubicin—thyroid cancer	0.000347	0.000898	CcSEcCtD
Trimethoprim—Pruritus—Doxorubicin—thyroid cancer	0.000343	0.000889	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000342	0.0032	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—HPGD—thyroid cancer	0.000338	0.00316	CbGpPWpGaD
Trimethoprim—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000337	0.00315	CbGpPWpGaD
Trimethoprim—Vomiting—Epirubicin—thyroid cancer	0.000333	0.000864	CcSEcCtD
Trimethoprim—Diarrhoea—Doxorubicin—thyroid cancer	0.000332	0.00086	CcSEcCtD
Trimethoprim—Rash—Epirubicin—thyroid cancer	0.00033	0.000856	CcSEcCtD
Trimethoprim—Dermatitis—Epirubicin—thyroid cancer	0.00033	0.000856	CcSEcCtD
Trimethoprim—Headache—Epirubicin—thyroid cancer	0.000328	0.000851	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000326	0.00305	CbGpPWpGaD
Trimethoprim—Dizziness—Doxorubicin—thyroid cancer	0.000321	0.000831	CcSEcCtD
Trimethoprim—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000315	0.00294	CbGpPWpGaD
Trimethoprim—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000313	0.00293	CbGpPWpGaD
Trimethoprim—Nausea—Epirubicin—thyroid cancer	0.000311	0.000807	CcSEcCtD
Trimethoprim—Vomiting—Doxorubicin—thyroid cancer	0.000308	0.000799	CcSEcCtD
Trimethoprim—TYMS—Cell Cycle—CDK1—thyroid cancer	0.000306	0.00286	CbGpPWpGaD
Trimethoprim—Rash—Doxorubicin—thyroid cancer	0.000306	0.000792	CcSEcCtD
Trimethoprim—Dermatitis—Doxorubicin—thyroid cancer	0.000305	0.000792	CcSEcCtD
Trimethoprim—Headache—Doxorubicin—thyroid cancer	0.000304	0.000787	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000294	0.00275	CbGpPWpGaD
Trimethoprim—Nausea—Doxorubicin—thyroid cancer	0.000288	0.000747	CcSEcCtD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000284	0.00266	CbGpPWpGaD
Trimethoprim—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000274	0.00257	CbGpPWpGaD
Trimethoprim—TYMS—Circadian rythm related genes—PTEN—thyroid cancer	0.000273	0.00255	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000269	0.00251	CbGpPWpGaD
Trimethoprim—DHFR—Disease—TPR—thyroid cancer	0.000265	0.00248	CbGpPWpGaD
Trimethoprim—DHFR—Disease—PRKAR1A—thyroid cancer	0.000261	0.00244	CbGpPWpGaD
Trimethoprim—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000255	0.00239	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—TERT—thyroid cancer	0.000253	0.00236	CbGpPWpGaD
Trimethoprim—CYP2C8—Biological oxidations—RXRA—thyroid cancer	0.000253	0.00236	CbGpPWpGaD
Trimethoprim—DHFR—Disease—MEN1—thyroid cancer	0.00025	0.00233	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—TPR—thyroid cancer	0.000222	0.00208	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—TERT—thyroid cancer	0.000221	0.00206	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—PRKAR1A—thyroid cancer	0.000219	0.00204	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000219	0.00204	CbGpPWpGaD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000218	0.00204	CbGpPWpGaD
Trimethoprim—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000206	0.00192	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000202	0.00189	CbGpPWpGaD
Trimethoprim—DHFR—Disease—CALCA—thyroid cancer	0.000199	0.00186	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—TPR—thyroid cancer	0.000194	0.00181	CbGpPWpGaD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000194	0.00181	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—PRKAR1A—thyroid cancer	0.000191	0.00178	CbGpPWpGaD
Trimethoprim—TYMS—Circadian rythm related genes—TP53—thyroid cancer	0.000186	0.00174	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—MINPP1—thyroid cancer	0.000186	0.00174	CbGpPWpGaD
Trimethoprim—DHFR—Disease—CDK1—thyroid cancer	0.00018	0.00168	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—SLC5A5—thyroid cancer	0.000166	0.00156	CbGpPWpGaD
Trimethoprim—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000164	0.00153	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.000163	0.00153	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—MINPP1—thyroid cancer	0.000162	0.00151	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—NDUFA13—thyroid cancer	0.000158	0.00148	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—MINPP1—thyroid cancer	0.000151	0.00141	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—CHST14—thyroid cancer	0.000148	0.00139	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—CCND1—thyroid cancer	0.000146	0.00137	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—SLC5A5—thyroid cancer	0.000145	0.00136	CbGpPWpGaD
Trimethoprim—DHFR—Disease—NRG1—thyroid cancer	0.000144	0.00135	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.000143	0.00133	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—RXRA—thyroid cancer	0.00014	0.00131	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—NDUFA13—thyroid cancer	0.000138	0.00129	CbGpPWpGaD
Trimethoprim—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000136	0.00127	CbGpPWpGaD
Trimethoprim—DHFR—Disease—TERT—thyroid cancer	0.00013	0.00121	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—CHST14—thyroid cancer	0.000129	0.00121	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—NDUFA13—thyroid cancer	0.000128	0.0012	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000128	0.00119	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000128	0.00119	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—CCND1—thyroid cancer	0.000127	0.00119	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000126	0.00118	CbGpPWpGaD
Trimethoprim—DHFR—Disease—HIF1A—thyroid cancer	0.000124	0.00116	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—RXRA—thyroid cancer	0.000122	0.00114	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—CHST14—thyroid cancer	0.000121	0.00113	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—HPGD—thyroid cancer	0.00012	0.00112	CbGpPWpGaD
Trimethoprim—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000118	0.00111	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—HPGD—thyroid cancer	0.000104	0.000974	CbGpPWpGaD
Trimethoprim—DHFR—Disease—BRAF—thyroid cancer	0.000103	0.00096	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000101	0.00094	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—MINPP1—thyroid cancer	9.97e-05	0.000932	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—HPGD—thyroid cancer	9.74e-05	0.00091	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	9.7e-05	0.000907	CbGpPWpGaD
Trimethoprim—DHFR—Cell Cycle—TP53—thyroid cancer	9.62e-05	0.0009	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.57e-05	0.000894	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	9.09e-05	0.000849	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—PPARG—thyroid cancer	8.83e-05	0.000825	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	8.77e-05	0.00082	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—NDUFA13—thyroid cancer	8.47e-05	0.000792	CbGpPWpGaD
Trimethoprim—TYMS—Cell Cycle—TP53—thyroid cancer	8.4e-05	0.000785	CbGpPWpGaD
Trimethoprim—DHFR—Disease—PTGS2—thyroid cancer	8.29e-05	0.000775	CbGpPWpGaD
Trimethoprim—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.04e-05	0.000752	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—CHST14—thyroid cancer	7.97e-05	0.000745	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	7.9e-05	0.000738	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—PPARG—thyroid cancer	7.7e-05	0.00072	CbGpPWpGaD
Trimethoprim—DHFR—Disease—PTEN—thyroid cancer	7.23e-05	0.000676	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—PTGS2—thyroid cancer	6.95e-05	0.000649	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—TPR—thyroid cancer	6.87e-05	0.000642	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	6.76e-05	0.000632	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	6.73e-05	0.00063	CbGpPWpGaD
Trimethoprim—DHFR—Disease—NRAS—thyroid cancer	6.45e-05	0.000603	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—HPGD—thyroid cancer	6.42e-05	0.0006	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.13e-05	0.000573	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—PTGS2—thyroid cancer	6.06e-05	0.000567	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—PTEN—thyroid cancer	6.06e-05	0.000566	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—TPR—thyroid cancer	5.99e-05	0.00056	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.99e-05	0.00056	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—PRKAR1A—thyroid cancer	5.89e-05	0.000551	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—TPR—thyroid cancer	5.59e-05	0.000523	CbGpPWpGaD
Trimethoprim—DHFR—Disease—KRAS—thyroid cancer	5.55e-05	0.000519	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	5.5e-05	0.000514	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—PTEN—thyroid cancer	5.29e-05	0.000494	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—SLC5A5—thyroid cancer	5.14e-05	0.000481	CbGpPWpGaD
Trimethoprim—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.05e-05	0.000473	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.99e-05	0.000466	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.82e-05	0.000451	CbGpPWpGaD
Trimethoprim—DHFR—Disease—HRAS—thyroid cancer	4.72e-05	0.000441	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—SLC5A5—thyroid cancer	4.48e-05	0.000419	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—RXRA—thyroid cancer	4.32e-05	0.000404	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.2e-05	0.000393	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—SLC5A5—thyroid cancer	4.19e-05	0.000391	CbGpPWpGaD
Trimethoprim—DHFR—Disease—AKT1—thyroid cancer	4.17e-05	0.00039	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.92e-05	0.000367	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—RXRA—thyroid cancer	3.77e-05	0.000352	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—TPR—thyroid cancer	3.69e-05	0.000345	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.63e-05	0.000339	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—RXRA—thyroid cancer	3.52e-05	0.000329	CbGpPWpGaD
Trimethoprim—DHFR—Metabolism—AKT1—thyroid cancer	3.49e-05	0.000326	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.42e-05	0.00032	CbGpPWpGaD
Trimethoprim—TYMS—Metabolism—AKT1—thyroid cancer	3.05e-05	0.000285	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.76e-05	0.000258	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—PPARG—thyroid cancer	2.73e-05	0.000255	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—PPARG—thyroid cancer	2.38e-05	0.000222	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—RXRA—thyroid cancer	2.32e-05	0.000217	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—PPARG—thyroid cancer	2.22e-05	0.000208	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—PTGS2—thyroid cancer	2.15e-05	0.000201	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—PTEN—thyroid cancer	1.87e-05	0.000175	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—PTGS2—thyroid cancer	1.87e-05	0.000175	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.75e-05	0.000163	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—PTEN—thyroid cancer	1.63e-05	0.000152	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—PTEN—thyroid cancer	1.52e-05	0.000142	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—PPARG—thyroid cancer	1.46e-05	0.000137	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.15e-05	0.000108	CbGpPWpGaD
Trimethoprim—CYP2C8—Metabolism—AKT1—thyroid cancer	1.08e-05	0.000101	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—PTEN—thyroid cancer	1e-05	9.39e-05	CbGpPWpGaD
Trimethoprim—ABCB1—Metabolism—AKT1—thyroid cancer	9.4e-06	8.79e-05	CbGpPWpGaD
Trimethoprim—CYP2C9—Metabolism—AKT1—thyroid cancer	8.78e-06	8.21e-05	CbGpPWpGaD
Trimethoprim—CYP3A4—Metabolism—AKT1—thyroid cancer	5.79e-06	5.41e-05	CbGpPWpGaD
